GlassScriptPhysician profile
Niyati Chiniwala
NPI 1528219367
$3,043.94
in general payments reported to CMS, 2019-2025
29 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $140 · 2021: $172 · 2022: $269 · 2023: $365 · 2024: $565 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,773.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $410.40 | 2019-2025 | Wegovy, Sogroya |
| Lilly USA, LLC | $307.41 | 2020-2025 | Jardiance, Mounjaro, Emgality |
| Abbott Laboratories | $305.74 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $273.50 | 2019-2022 | |
| Corcept Therapeutics | $230.04 | 2019-2025 | Korlym |
| Ibsa Pharma INC. | $206.14 | 2019-2025 | Licart, Flector, Tirosint |
| Abbvie INC. | $193.49 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $143.36 | 2024-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $128.33 | 2019-2025 | |
| Amarin Pharma, INC. | $127.45 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.68 | 2023-2024 | |
| Amgen INC. | $82.52 | 2019-2025 | Tepezza |
| Insulet Corporation | $80.95 | 2019-2025 | Omnipod |
| Radius Health, INC. | $66.10 | 2025 | Tymlos |
| Dexcom, INC. | $62.91 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $49.88 | 2025 | Rezdiffra |
| Pfizer INC. | $40.45 | 2024-2025 | |
| Exact Sciences Corporation | $32.15 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $30.77 | 2019 | |
| Lifescan, INC. | $26.26 | 2021-2022 | |
| Sequel Med Tech, LLC | $14.59 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $14.51 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.49 | 2022 | |
| Astellas Pharma US INC | $14.42 | 2024 | Veozah |
| Medtronic, INC. | $13.91 | 2023 | Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $13.83 | 2025 | Shingrix |
| Phathom Pharmaceuticals, INC. | $13.81 | 2024 | Voquezna |
| Mannkind Corporation | $13.29 | 2024 | |
| Xeris Pharmaceuticals, INC. | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niyati Chiniwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.